Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO - report
⇨ A year after its lead cancer drug flopped in Phase III, Peregrine Pharmaceuticals $PPHM is bringing out the ax and slashing its staff by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
